Atopic Dermatitis in Older Adults: A Review of Treatment Options
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bieber T. Personalized management of atopic dermatitis: beyond emollients and topical steroids. In: Bieber T, Nestle F, editors. Personalized treatment options in dermatology. Berlin: Springer; 2015. p. 61–76.
Sulzberger MB, Goodman J. The relative importance of specific skin hypersensitivity in adult atopic dermatitis. JAMA. 1936;106:1000–3.
Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol. 2014;150(6):593–600.
Bozek A, Fisher A, Filipowska B, Mazur B, Jazab J. Clinical features and immunological markers of atopic dermatitis in elderly patients. Int Arch Allergy Immunol. 2012;157:372–8.
Tanei R, Hasegawa Y, Sawabe M. Abundant immunoglobulin E-positive cells in skin lesions support an allergic etiology of atopic dermatitis in the elderly. J Eur Acad Dermatol Venereol. 2013;27:952–60.
Tanei R. Clinical characteristics, treatments, and prognosis of atopic eczema in the elderly. J Clin Med. 2015;4:979–97.
Zhou L, Leonard A, Pavel AB, Malik K, Raja A, Glickman J, et al. Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2019;144(1):144–56.
Silverberg JI, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, et al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019;33(7):1341–8.
Bieber T, D’Erme AM, Akdis CA, Traidl-Hoffmann C, Lauener R, Schäppi G, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol. 2017;139:S58–64.
Tanei R, Hasegawa Y. Atopic dermatitis in older adults: a viewpoint from geriatric dermatology. Geriatr Gerontol Int. 2016;16(Suppl. 1):75–86.
Katsarou A, Armenaka MC. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol. 2011;25:12–8.
Irawan Y, Rihatmadja R, Legiawait L, Yusharyahya SN, Sularsito SA. Atopic dermatitis in the elderly. J Gen Pro DVI. 2016;1:54–61.
Tanei R. Senile atopic dermatitis. In: Katayama I, Murota H, Satoh T, editors. Evolution of atopic dermatitis in the 21st century. Singapore: Springer; 2018. p. 229–48.
Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks. Br J Dermatol. 2020;182(1):47–54.
He H, Li R, Choi S, Zhou L, Pavel A, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis. Ann Allergy Asthma Immunol. 2020;124:70–8.
Park JH, Choi YL, Namkung JH, Kim WS, Lee JH, Park HJ, et al. Characteristics of extrinsic and intrinsic atopic dermatitis in infancy: correlations with laboratory variables. Br J Dermatol. 2006;155:778–83.
Tanei R, Hasegawa Y. Double-positive immunoglobulin E + and Dermatophagoides farinae antigen + dendritic cells are observed in skin lesions of older adults with atopic dermatitis: an immunohistological study. Dermatol Clin Res. 2017;3(1):134–50.
Aoki T, Fukuzumi T, Adachi J, Endo K, Kojima M. Re-evaluation of skin lesion distribution in atopic dermatitis. Analysis of cases 0 to 9 years of age. Acta Derm Venereol Suppl (Stockh). 1992;176:19–23.
Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134:769–79.
Furue M, Chiba T, Tsuji G, Ulzii D, Kido-Nakahara M, Nakahara T, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66:398–403.
Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. Allergy Clin Immunol. 2016;138:336–49.
Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140:633–43.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venerol (Stockh). 1980;92:44–7.
Camacho FM, García-Hernandez MJ, Muñoz-Pérez MA, Mazuecos J, Sotillo I. Ofuji papuloerythroderma in elderly woman with atopic erythroderma. J Eur Acad Dermatol Venereol. 2001;15:264–6.
Miyagaki T, Sugaya M. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. J Dermatol Sci. 2011;64:1–6.
Hüls A, Abramson M, Sugiri D, Fuks K, Krämer U, Krutmann J, et al. Nonatopic eczema in elderly women: effect of air pollution and genes. J Allergy Clin Immunol. 2019;143:378–85.
Brummer GC, Wang LT, Sontheimer RD. A possible role for dupilumab (Dupixent) in the management of idiopathic chronic eczematous eruption of aging. Dermatol Online J. 2018;24(2):3.
Nakano-Tahara M, Terao M, Nishioka M, Kitaba S, Murota H, Katayama I. T helper 2 polarization in senile erythroderma with elevated levels of TARC and IgE. Dermatology. 2015;230:62–9.
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol. 2018;121:604–12.
Shaheen MS, Silverberg JI. Atopic dermatitis is associated with osteoporosis and osteopenia in older adults. J Am Acad Dermatol. 2019;80:550–1.
Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Investig Dermatol. 2017;137:18–25.
Kataoka Y. Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol. 2014;41:221–9.
Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46:1053–101.
Katayama I, Aihara M, Ohya Y, Saeki H, Shimojo N, et al. Japanese guidelines for atopic dermatitis 2017. Allergo Int. 2017;66:230–47.
Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139(4S):S49–57.
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS), et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32:657–82.
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS), et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32:850–78.
Hoare C, Po ALW, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1–191.
Tan BB, Weald D, Strickland I, Freidmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet. 1996;347(8993):15–8.
Hide M, Tanaka T, Yamamura Y, Koro O, Yamamoto S. IgE-mediated hypersensitivity against human sweat antigen in patients with atopic dermatitis. Acta Derm Venereol. 2002;82:335–40.
Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66:8–13.
Barbarot S, Stalder JF. Therapeutic patient education in atopic eczema. Br J Dermatol. 2014;170:44–8.
Teplitsky V, Mumcuoglu KY, Babai I, Dalal I, Cohen R, Tanay A. House dust mites on skin, clothes, and bedding of atopic dermatitis patients. Int J Dermatol. 2008;47(8):790–5.
Yasueda H, Saito A, Nishioka K, Kutsuwada K, Akiyama K. Measurement of Dermatophagoides mite allergens on bedding and human skin surfaces. Clin Exp Allergy. 2003;33:1654–8.
Simpson A, Simpson B, Custovic A, Cain G, Craven M, Woodcock A. Household characteristics and mite allergen levels in Manchester, UK. Clin Exp Allergy. 2002;32:1413–9.
Yosipovitch G. Dry skin and impairment of barrier function associated with itch—new insights. Int J Cosmet Sci. 2004;26(1):1–7.
Katoh N, Tennstedt D, van Kan AG, Saint Aroman M, Loir A, Bacqueville D, et al. Gerontodermatology: the fragility of the epidermis in older adults. J Eur Acad Dermatol Venereol. 2018;32(Suppl 4):1–20.
Brunner PM, Khattri S, Garcet S, Finney R, Oliva M, Dutt R, et al. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2016;138:169–78.
Suzuki T, Uchino T, Miyazaki Y, Kagawa Y. The effect of storage time on the release profile of dexamethasone dipropionate from admixtures of steroid and heparinoid ointment. Pharmazie. 2014;69:104–8.
Butler JM, Chan SC, Stevens S, Hanifin JM. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol. 1983;71:490–7.
Ikoma A, Rukwied R, Ständer S, Steinhoff M, Miyachi Y, Schmelz M. Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol. 2003;139:1455–8.
Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol. 2003;148:1212–21.
Kawashima M, Furue M, Hide M, et al. A comparative study of anti-pruritic effects and the occurrence of drowsiness between sedating and non-sedating antihistamines (ACROSS trial) (in Japanese). J Clin Ther Med. 2011;27:563–73.
van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z, Jupiter A, Matterne U, Weisshaar E. No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review. Syst Rev. 2014;3:25.
Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev. 2019;1:CD012167.
Paganelli R, Levinsky RJ, Brostoff J, Wraith DG. Immune complexes containing food proteins in normal and atopic subjects after oral challenge and effect of sodium cromoglycate on antigen absorption. Lancet. 1979;1(8129):1270–2.
Pigatto PD, Gibelli E, Fumagalli M, Bigardi A, Morelli M, Altomare GF. Disodium cromoglycate versus diet in the treatment and prevention of nickel-positive pompholyx. Contact Dermat. 1990;22:27–31.
Gorai S, Terada N, Kobayashi T, Nomura T, Kim WJ, Onai N, et al. The effect of suplatast tosilate on TARC production in peripheral blood mononuclear cells and TARC plasma levels. Allergo Int. 2005;54:373–80.
Megna M, Napolitano M, Patruno C, Villani A, Balato A, Monfrecola G, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7:1–23.
Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78:733–40.
Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178:768–75.
Jackson SM, Nesbitt LT. Glucocorticosteroids. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology, vol. 1. 3rd ed. Amsterdam: Elsevier; 2012. p. 2075–88.
Furue M. Topical corticosteroids: how to use in clinical practice (in Japanese). Arerugi. 2009;58:491–8.
Aso M. The effects of potent topical corticosteroids on adrenocortical function. J Dermatol. 1983;10:145–9.
Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med. 2005;257:374–84.
Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32:337–50.
Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215–9.
Aguirre R, May JM. Inflammation in the vascular bed: importance of vitamin C. Pharmacol Ther. 2008;119:96–103.
Ogawa S, Oka M, Kunisada M, Nishigori C. Unilateral lower leg purpura. Dermatol Online J. 2013;19(1):16.
Fisher DA. Adverse effects of topical corticosteroid use. West J Med. 1995;162:123–6.
Dezoteux F, Astrid B, Chuffard M, Drumez E, Azib S, Staumont-Sallé D. Atopic dermatitis in elderly adults. Eur J Dermatol. 2019;29(4):371–4. https://doi.org/10.1684/ejd.2019.3609.
Garritsen FM, van der Schaft J, van den Reek JM, Politiek K, van Os-Medendorp H, van Dijk M, et al. Risk of non-melanoma skin cancer in patients with atopic dermatitis treated with oral immunosuppressive drugs. Acta Derm Venereol. 2017;97:724–30.
Sinha A, Velangi S, Natarajan S. Non-Hodgkin’s lymphoma following treatment of atopic eczema with cyclosporin A. Acta Derm Venereol. 2004;84:327–8.
van der Schaft J, van Zuilen AD, Deinum J, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Serum creatinine levels during and after long-term treatment with cyclosporine A in patients with severe atopic dermatitis. Acta Derm Venereol. 2015;95:963–7.
Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. Discov Med. 2011;11(61):537–50.
Tanei R, Oda A, Hasegawa Y. Narrow-band ultraviolet B is a useful adjunctive treatment for atopic dermatitis in older adults: case reports. Dermatol Clin Res. 2016;2(3):112–7.
Tintle S, Shemer A, Suárez-Fariñas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol. 2011;128:583–93.
Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–9.
Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015;7:1043–58.
Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, Ming JE, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293–300.
Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:155–72.
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178:1083–101.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–96.
Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegräber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6:1778–80.
Fukuda K, Ishida W, Kishimoto T, Fukushima A. Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis. Allergol Int. 2019;68:383–4.
Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020;82(1):230–2.
de Beer FSA, Bakker DS, Haeck I, Ariens L, van der Schaft J, van Dijk MR, et al. Dupilumab facial redness: positive effect of itraconazole. JAAD Case Rep. 2019;5:888–91.
Suresh R, Murase JE. The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy. JAAD Case Rep. 2018;4:899–904.
Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75:494–503.
Fabbrocini G, Napolitano M, Megna M, Balato N, Patruno C. Treatment of atopic dermatitis with biologic drugs. Dermatol Ther (Heidelb). 2018;8:527–38.